Cases & Deals

  • Home
  • Practices
  • Reverse sale of Genticel to GenKyoTex SA to become Genkyotex

Share

Reverse sale of Genticel to GenKyoTex SA to become Genkyotex

February 2017

Client(s) Genticel S.A.

Jones Day advised Genticel SA in connection with its reverse sale to the shareholders of GenKyoTex who received approximately 80 percent of the share capital of Genticel in remuneration of their contribution of GenKyoTex shares to Genticel.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.